Precision Medicine In Psychiatry: Astellas Joins Search For Biomarkers, Drug Targets
Biomarkers for psychiatric disorders are lacking, but Astellas is investing in its own and external efforts to identify drug targets as well as patients who'll respond to new therapies.
You may also be interested in...
Progress has been made in areas such as lung and breast cancer, but panelists at a recent conference noted there are many efficiencies yet to be realized in drug development and reimbursement.
The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.
At a time of resurgent interest in CNS, The Lieber Institute for Brain Development’s capabilities and tissue resources set it apart from other brain research initiatives. The privately backed research lab is focused on translating genetic clues to the cause and course of schizophrenia and related disorders into new treatments.